Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ME-PR
- Development stage
- Unknown
- Lead developer
- Systopic Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ME-PR is a fixed-dose combination capsule containing pregabalin (75 mg) and methylcobalamin (750 mcg), developed and marketed by Systopic Laboratories. It is primarily indicated for the treatment of neuropathic pain, including diabetic neuropathy and peripheral neuropathy. Pregabalin acts as an alpha-2-delta ligand that binds to voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters and alleviating pain. Methylcobalamin, an active form of vitamin B12, serves as a cofactor for methionine synthase, promoting myelin sheath synthesis, axonal regeneration, and the rejuvenation of damaged nerve cells. Together, the two components provide synergistic relief from nerve pain and support nerve repair.
- Brand names
- ME-PRME-PR Capsule
- Other names
- mecobalamin + pregabalinmethylcobalamin + pregabalinpregabalin + mecobalaminpregabalin + methylcobalamin
02
Targets
MTR (Methionine synthase)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)α2δ (Voltage-gated calcium channel alpha-2-delta subunit)
Beyond the preview
Go deeper on ME-PR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ME-PR.